CSL has released its FY2025 results, with the company recording a "strong performance", with 5% revenue growth and a 17% increase in net profit after tax for the year.
Also announced at yesterday's presentation was that the company will shed 3,000 jobs globally - around 15% of its workforce.
Shares plunged by 17% over the day following the announcements.
Growth was largely driven by blood plasma business CSL Behring and iron deficiency arm CSL Vifor.
Its vaccines business, CSL Seqiris, has been impacted by anti-vax sentiment in the US, experiencing lower growth than the other business arms.
CSL announced it intends to demerge Seqirus into a separate ASX-listed business in 2026, pending third-party consent, regulatory approvals and shareholder support.
It will then combine its blood plasma and iron deficiency businesses into one unit.
The restructure is expected to cost $700 million, but will result in savings of around $500 million to $550 million per year, of which half will be reinvested back in the company and the rest returned to shareholders.
"CSL Seqirus continued to show the resilience of its differentiated portfolio and platforms by generating growth in a challenging environment," said CEO Dr Paul McKenzie, referring to uncertainty related to US President Trump's tariffs on pharmaceuticals.
"We firmly believe that a simplified and focused CSL is best for patients, best for our people, and best for our shareholders.
"The changes announced today will deliver enduring patient value and durable shareholder returns." KB
The above article was sent to subscribers in Pharmacy Daily's issue from 20 Aug 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Aug 25
